Myocarditis/pericarditis Following Vaccination with BNT162b2, CoronaVac, and ChAdOx1 Among Adolescent and Adult in Malaysia

Overview

Journal Vaccine X

Date 2023 Apr 24

PMID 37091730

Authors

Norazida Ab Rahman

Ming Tsuey Lim

Fei Yee Lee

Emelyne Bani Anak Jam

Kalaiarasu M Peariasamy

Sheamini Sivasampu

Affiliations

Soon will be listed here.

Abstract

This study evaluates 21-day risk of myocarditis/pericarditis following COVID-19 vaccination among those aged 12 years and older in Malaysia. We used data from nationwide COVID-19 vaccine registry linked to hospital episode database to identify individuals vaccinated with BNT162b2, CoronaVac, or ChAdOx1 and hospitalised for myocarditis/pericarditis between 1 February 2021 and 28 February 2022. There were 87 myocarditis/pericarditis cases identified within 1-21 days after vaccination. Most cases were reported following BNT16262 vaccination (77.0%) with absolute risk of 0.33 cases/100,000 vaccinated persons or 1.73 per million doses administered. Highest risk was observed following second dose and in younger, male individuals. The risk of myocarditis/pericarditis following CoronaVac and ChAdOx1 were much lower compared to BNT162b2. The findings on higher risk observed among younger following mRNA vaccine were consistent with literature and important for targeted surveillance.

Citing Articles

Myocarditis and Pericarditis are Temporally Associated with BNT162b2 COVID-19 Vaccine in Adolescents: A Systematic Review and Meta-analysis.

Choi Y, Lee J, Choe Y, Lee H, Yoon Y, Shin S Pediatr Cardiol. 2024; .

PMID: 39404761 DOI: 10.1007/s00246-024-03618-2.

COVID-19 Vaccine-Induced Myocarditis and Pericarditis: Towards Identification of Risk Factors.

Zwiers L, Ong D, Grobbee D Glob Heart. 2024; 18(1):39.

PMID: 38533475 PMC: 10964799. DOI: 10.5334/gh.1252.

References

Chen C, Fu F, Ding L, Fang J, Xiao J . Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system. Front Immunol. 2022; 13:938322. PMC: 9510366. DOI: 10.3389/fimmu.2022.938322. View

Pillay J, Gaudet L, Wingert A, Bialy L, Mackie A, Paterson D . Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. BMJ. 2022; 378:e069445. PMC: 9277081. DOI: 10.1136/bmj-2021-069445. View

Yap J, Tham M, Poh J, Toh D, Chan C, Lim T . Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting. Ann Acad Med Singap. 2022; 51(2):96-100. View

Lai F, Li X, Peng K, Huang L, Ip P, Tong X . Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine : A Case-Control Study. Ann Intern Med. 2022; 175(3):362-370. PMC: 8814917. DOI: 10.7326/M21-3700. View

Karlstad O, Hovi P, Husby A, Harkanen T, Selmer R, Pihlstrom N . SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. JAMA Cardiol. 2022; 7(6):600-612. PMC: 9021987. DOI: 10.1001/jamacardio.2022.0583. View

Su W, Liu Y, Chang C, Lin Y, Huang W, Wu L . Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-A nationwide study. J Microbiol Immunol Infect. 2023; 56(3):558-565. PMC: 9907782. DOI: 10.1016/j.jmii.2023.01.016. View

Corrao G, Franchi M, Cereda D, Bortolan F, Leoni O, Vignati E . Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy. BMC Infect Dis. 2022; 22(1):844. PMC: 9652976. DOI: 10.1186/s12879-022-07823-3. View

Patone M, Mei X, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M . Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. Circulation. 2022; 146(10):743-754. PMC: 9439633. DOI: 10.1161/CIRCULATIONAHA.122.059970. View

Patone M, Mei X, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M . Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2021; 28(2):410-422. PMC: 8863574. DOI: 10.1038/s41591-021-01630-0. View

10.

Chou O, Zhou J, Lee T, Kot T, Lee S, Wai A . Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study. Clin Res Cardiol. 2022; 111(10):1098-1103. PMC: 8951670. DOI: 10.1007/s00392-022-02007-0. View

11.

Ling R, Ramanathan K, Tan F, Tai B, Somani J, Fisher D . Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis. Lancet Respir Med. 2022; 10(7):679-688. PMC: 9000914. DOI: 10.1016/S2213-2600(22)00059-5. View

12.

Husin M, Tok P, Suah J, Thevananthan T, Tng B, Peariasamy K . Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia. Int J Infect Dis. 2022; 121:55-57. PMC: 9055416. DOI: 10.1016/j.ijid.2022.04.053. View

13.

Ab Rahman N, Lim M, Lee F, Ong S, Peariasamy K, Sivasampu S . A Case-Based Monitoring Approach to Evaluate Safety of COVID-19 Vaccines in a Partially Integrated Health Information System: A Study Protocol. Front Pharmacol. 2022; 13:834940. PMC: 9328743. DOI: 10.3389/fphar.2022.834940. View

14.

Wong H, Hu M, Zhou C, Lloyd P, Amend K, Beachler D . Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Lancet. 2022; 399(10342):2191-2199. PMC: 9183215. DOI: 10.1016/S0140-6736(22)00791-7. View

15.

Chua G, Kwan M, Chui C, Smith R, Cheung E, Ma T . Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. 2021; 75(4):673-681. PMC: 8767823. DOI: 10.1093/cid/ciab989. View

16.

Bozkurt B, Kamat I, Hotez P . Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021; 144(6):471-484. PMC: 8340726. DOI: 10.1161/CIRCULATIONAHA.121.056135. View

17.

Buchan S, Seo C, Johnson C, Alley S, Kwong J, Nasreen S . Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada. JAMA Netw Open. 2022; 5(6):e2218505. PMC: 9233237. DOI: 10.1001/jamanetworkopen.2022.18505. View

18.

Wang X, Bu X, Wei L, Liu J, Yang D, Mann D . Global, Regional, and National Burden of Myocarditis From 1990 to 2017: A Systematic Analysis Based on the Global Burden of Disease Study 2017. Front Cardiovasc Med. 2021; 8:692990. PMC: 8284556. DOI: 10.3389/fcvm.2021.692990. View